Ultime notizie per Ferguson Enterprises (NYSE:FERG) Azioni

FERGUSON ENTERPRISES INC

Ferguson Enterprises

Ferguson

Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.

Dollar General

Markets

CRDO

FERG

MLTX

Tra utili attesi e voci di un deal miliardario, il mercato si muove. Riflettori su retail, tech e una biotech sotto osservazione.

Dollar General, Signet Jewelers e 3 altre azioni da tenere d&#39;occhio oggi

Central,City,Illinois,-,May,2018:,Dollar,General,Sign,Against

Ferguson Enterprises Inc

Volcon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) is doubling down on its pivot to Bitcoin, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46629776/volcon-initiates-strategic-bitcoin-treasury-program-and-expands-share-repurchase-authorization-to-" rel="noreferrer noopener">revealing that it now holds</a> over 3,183 Bitcoin (CRYPTO: BTC/USD) on its balance sheet, valued at roughly $375 million as of July 25. The company, which has roots in electric off-road vehicles, is now embracing a treasury strategy built around digital assets.
Co-CEO Ryan Lane said the move signals Volcon&#8217;s belief in Bitcoin as a resilient long-term asset and a smart reserve choice. As of 8 a.m. ET on Thursday, Volcon had acquired 3,183.37 BTC at an average cost of $117,697 per coin.
Alongside its aggressive crypto acquisition, Volcon&#8217;s board approved a sizable increase to its stock buyback program, raising the limit to $100 million.
The initiative, set to run over the next 24 months, allows for open-market and private repurchases, giving Volcon room to bolster its net asset value (NAV) per share and, potentially, boost BTC per share metrics if share prices fall below NAV.
Also Read: <a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46629919/why-are-public-companies-ammassing-eth-xrp-sol-bnb-instead-of-just-bitcoin" rel="noreferrer noopener">Why Are Public Companies Ammassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin?</a>
Volcon also disclosed that it has sold short-dated put options with strike prices of $115,000, $116,000, and $117,000, generating option premiums to help reduce its average Bitcoin acquisition cost. Lane emphasized that Volcon plans to continue using advanced financial strategies, drawing from its leadership&#8217;s hedge fund background, to scale its crypto reserves efficiently.
The company&#8217;s recent <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46470641/volcon-vlcn-stock-soars-on-500m-funding-and-strategic-pivot-to-bitcoin" rel="noreferrer noopener">strategic pivot to Bitcoin</a> follows a $500 million capital raise, positioning Volcon as a rare public-market entry point for direct Bitcoin exposure. This realignment reflects broader investor appetite for alternatives to traditional equity plays in the crypto space.
Founded as an all-electric powersports brand, Volcon has since expanded its mission. As of mid-July, the company officially adopted a Bitcoin-first treasury approach to become a low-cost, capital-efficient leader in the digital asset space. Its electric vehicles remain central to the brand, but now serve as one half of a hybrid identity blending renewable mobility and decentralized finance.
Related ETFs include ProShares Bitcoin Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITO#NYSE">BITO</a>) and Grayscale Bitcoin Trust (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>).
Price Action: VLCN shares are trading higher by 5.01% to $14.25 on Friday&#8217;s last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46627515/bitcoin-slips-below-117000-on-whale-selling-ethereum-xrp-hold-steady" target="_blank" rel="noreferrer noopener">Bitcoin Slips Below $117,000 On Whale Selling, Ethereum, XRP Hold Steady</a></li>
</ul>
Photo via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Buybacks

Movers

$BTC

BITO

GBTC

VLCN

Volcon Deepens Bitcoin Bet, Boosts Share Buyback

RBC Capital analyst Jon Arfstrom maintains Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Outperform and raises the price target from $10 to $11.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Valley Ntl, Raises Price Target to $11

<a href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025" title="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025">https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025</a>

Biotech

Global

General

MRNA

EMA's CHMP Adopts Positive Opinion Recommending Authorization Of Moderna's Covid-19 MRNA Vaccine Targeting The SARS-CoV-2 Variant LP.8.1; Updated Covid-19 MRNA Vaccine Will Be Available For 2025-2026 Vaccination Season, Pending European Commission Authorization Decision

AMTD Group Inc. ("AMTD" or the "Group"), alongside The Generation Essentials Group ("TGE"), a subsidiary of the Group under AMTD Digital, jointly announce that as a global owner of fashion magazines published under "L'OFFICIEL AMTD" and its associated brands, we have recently won two more successful actions against IP infringers Luxury Village LLC and its director Dimitri Vorontsov ("IP infringers") for their infringing and improper conduct.
On 29 July 2024, we successfully obtained a Hong Kong court order, case number HKIP 73 / 2023 mandating these IP infringers to cease prohibited operations and relinquish domain names wrongfully incorporating "lofficiel". However, Luxury Village LLC has since continued to operate &lt;lofficiel.au&gt; and &lt;lofficielfashionbook.hk&gt; and published digital copies of "L'Officiel Fashion Book" magazines in breach of the court order.&nbsp; We will not tolerate such IP infringement and have subsequently successfully obtained court decisions against Luxury Village LLC, which have resulted in the transfer of the domain names &lt;lofficiel.au&gt; (WIPO case no: DAU 2025-008) and &lt;lofficielfashionbook.hk&gt; (HKIAC case no: DHK-2400211) back to us.
Further to the victory in the aforementioned domain name proceedings, we are pleased to announce that AMTD secured another major victory on July 25, 2025, successfully blocking the bad faith application by Luxury Village LLC of a "L'OFFICIEL FASHION BOOK" trade mark in Australia - Australian Trade mark number 2289204, Decision Number 2025 ATMO 145.&nbsp;
In this decision, the Registrar of Trade Marks of IP Australia ("the "Registrar") decided that "L'OFFICIAL FASHION BOOK" must be refused registration on the basis that Luxury Village LLC made the trade mark application in bad faith. The Registrar's decision reinforces that Luxury Village LLC has acted and continues to act in bad faith which infringes AMTD's rights. An extract from the Registrar's decision is set out below: "A reasonable person standing in the shoes of [Luxury Village LLC] should have considered themselves constrained from applying for the Trade Mark on the basis of the previous dealings between AMTD and TGE, as well as the Director of the Applicant company and that in all the circumstances surrounding this matter, the Application was made in bad faith".
These legal rulings and decisions underscore the protection of AMTD's intellectual property rights and highlights the bad faith actions of Luxury Village LLC in using domain name for commercial gain, misleadingly suggesting an affiliation with AMTD. The Registrar's decision also reaffirms the rights of AMTD and TGE in IP protection, ensuring the protection of our brands and intellectual property.
We remain steadfast in maintaining the integrity of our brands and will continue to take prompt and decisive actions to safeguard our trademarks globally. We have also successfully taken down other infringing domain names such as &lt;lofficiel.co&gt;, &lt;lofficiel.co.com&gt;, &lt;lofficiel.cn&gt;, &lt;lofficiel.net.cn&gt;, &lt;lofficielengland.com&gt;, and &lt;lofficielitaly.com&gt; being illicit attempts to exploit our international profile and growth.

AMTD

AMTD Wins Major IP Battles Against Luxury Village LLC Over "L'OFFICIEL" Infringements, Secures Domain Transfers and Trademark Rejection

RBC Capital analyst Sam Crittenden maintains Teck Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TECK#TSX">TECK</a>) with a Outperform and lowers the price target from C$82 to C$67.

TSX:TECK

TSX:TECK/B

RBC Capital Maintains Outperform on Teck Resources, Lowers Price Target to C$67

The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025
ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis
Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- &nbsp;Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory ("I&amp;I") diseases, today announced the completion of its previously announced merger&nbsp;with Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) ("Ikena"). The combined company will operate under the name ImageneBio, Inc. ("ImageneBio") and will trade on The Nasdaq Capital Market ("Nasdaq") under the ticker symbol "IMA" beginning at market open on July 28, 2025.
Concurrent with the closing of the merger, Inmagene and Ikena completed a&nbsp;$75.0 million&nbsp;private placement with a syndicate of existing and new investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will be led by Kristin Yarema, Ph.D. as its Chief Executive Officer, as announced earlier this week.

IKNA

Inmagene And Ikena Complete Merger To Form ImageneBio, Inc., Begin Trading On Nasdaq Under "IMA" July 28, 2025; Secures $75M Financing, Advances Phase 2b Trial Of Anti-OX40 Antibody IMG-007 For Atopic Dermatitis

Barclays analyst Mark Devries maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Overweight and raises the price target from $38 to $43.

Barclays Maintains Overweight on SLM, Raises Price Target to $43

Enterprise Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSC#NASDAQ">EFSC</a>) is set to give its latest quarterly earnings report on Monday, 2025-07-28. Here's what investors need to know before the announcement.
Analysts estimate that Enterprise Finl Servs will report an earnings per share (EPS) of $1.20. 
The announcement from Enterprise Finl Servs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.14, which was followed by a 0.62% drop in the share price the next day.
Here's a look at Enterprise Finl Servs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.17</td>
<td>1.16</td>
<td>1.14</td>
<td>1.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.31</td>
<td>1.32</td>
<td>1.29</td>
<td>1.21</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>3.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455773_0.png" alt="eps graph" />
<h3>Tracking Enterprise Finl Servs's Stock Performance</h3>
Shares of Enterprise Finl Servs were trading at $56.2 as of July 24. Over the last 52-week period, shares are up 6.08%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/EFSC/earnings">To track all earnings releases for Enterprise Finl Servs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

EFSC

An Overview of Enterprise Finl Servs's Earnings

Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) is preparing to release its quarterly earnings on Monday, 2025-07-28. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Brixmor Property Group to report an earnings per share (EPS) of $0.35.
Investors in Brixmor Property Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 4.23% drop in the share price on the subsequent day.
Here's a look at Brixmor Property Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.55</td>
<td>0.54</td>
<td>0.53</td>
<td>0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.53</td>
<td>0.52</td>
<td>0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455762_0.png" alt="eps graph" />
<h3>Performance of Brixmor Property Group Shares</h3>
Shares of Brixmor Property Group were trading at $25.79 as of July 24. Over the last 52-week period, shares are up 4.13%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analysts' Perspectives on Brixmor Property Group</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Brixmor Property Group.
The consensus rating for Brixmor Property Group is Buy, based on 4 analyst ratings. With an average one-year price target of $29.0, there's a potential 12.45% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of NNN REIT, Agree Realty and Federal Realty Investment, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for NNN REIT, with an average 1-year price target of $43.8, suggesting a potential 69.83% upside.</li>
<li>Analysts currently favor an Buy trajectory for Agree Realty, with an average 1-year price target of $79.83, suggesting a potential 209.54% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Federal Realty Investment, with an average 1-year price target of $108.0, suggesting a potential 318.77% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for NNN REIT, Agree Realty and Federal Realty Investment are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brixmor Property Group</td>
<td>Buy</td>
<td>5.39%</td>
<td>$253.41M</td>
<td>2.34%</td>
</tr>
<tr>
<td>NNN REIT</td>
<td>Neutral</td>
<td>7.17%</td>
<td>$221.48M</td>
<td>2.21%</td>
</tr>
<tr>
<td>Agree Realty</td>
<td>Buy</td>
<td>13.19%</td>
<td>$148.78M</td>
<td>0.83%</td>
</tr>
<tr>
<td>Federal Realty Investment</td>
<td>Outperform</td>
<td>6.12%</td>
<td>$204.78M</td>
<td>2.03%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Brixmor Property Group ranks in the middle for Consensus rating. It is at the bottom for Revenue Growth. It is at the top for Gross Profit. It is at the top for Return on Equity.
<h3>Delving into Brixmor Property Group's Background</h3>
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
<h3>Brixmor Property Group: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Brixmor Property Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.39% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Brixmor Property Group's ROE excels beyond industry benchmarks, reaching 2.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.79%, the company showcases effective utilization of assets.
Debt Management: Brixmor Property Group's debt-to-equity ratio is below the industry average. With a ratio of 1.73, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/BRX/earnings">To track all earnings releases for Brixmor Property Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Brixmor Property Group

RBC Capital analyst Sam Crittenden maintains Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) with a Outperform and lowers the price target from $82 to $67.

TECK

RBC Capital Maintains Outperform on Teck Resources, Lowers Price Target to $67

Bank of Hawaii (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOH#NYSE">BOH</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Bank of Hawaii will report an earnings per share (EPS) of $1.04.
The announcement from Bank of Hawaii is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 3.77% increase in the share price on the subsequent day.
Here's a look at Bank of Hawaii's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.89</td>
<td>0.83</td>
<td>0.82</td>
<td>0.86</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.97</td>
<td>0.85</td>
<td>0.93</td>
<td>0.86</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455752_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bank of Hawaii were trading at $66.0 as of July 24. Over the last 52-week period, shares are down 1.44%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BOH/earnings">To track all earnings releases for Bank of Hawaii visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Bank of Hawaii's Earnings Preview

Ameris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Ameris to report an earnings per share (EPS) of $1.33.
The market awaits Ameris's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 3.58% increase in the share price on the subsequent day.
Here's a look at Ameris's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.14</td>
<td>1.19</td>
<td>1.25</td>
<td>1.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.28</td>
<td>1.38</td>
<td>1.38</td>
<td>1.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455740_0.png" alt="eps graph" />
<h3>Tracking Ameris's Stock Performance</h3>
Shares of Ameris were trading at $65.68 as of July 24. Over the last 52-week period, shares are up 7.43%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ABCB/earnings">To track all earnings releases for Ameris visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABCB

Examining the Future: Ameris's Earnings Outlook

Telefonica Brasil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIV#NYSE">VIV</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Telefonica Brasil will report an earnings per share (EPS) of $0.12.
The announcement from Telefonica Brasil is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.01, leading to a 5.87% increase in the share price on the subsequent day.
Here's a look at Telefonica Brasil's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.120</td>
<td>0.19</td>
<td>0.16</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.111</td>
<td>0.19</td>
<td>0.18</td>
<td>0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455728_0.png" alt="eps graph" />
<h3>Tracking Telefonica Brasil's Stock Performance</h3>
Shares of Telefonica Brasil were trading at $11.07 as of July 24. Over the last 52-week period, shares are up 28.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Telefonica Brasil</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Telefonica Brasil.
The consensus rating for Telefonica Brasil is Buy, based on 2 analyst ratings. With an average one-year price target of $11.4, there's a potential 2.98% upside.
<h3>Comparing Ratings with Competitors</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Verizon Communications and AT&amp;T, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Verizon Communications, with an average 1-year price target of $47.88, suggesting a potential 332.52% upside.</li>
<li>Analysts currently favor an Buy trajectory for AT&amp;T, with an average 1-year price target of $31.75, suggesting a potential 186.81% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Verizon Communications and AT&amp;T are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shenandoah</td>
<td>Buy</td>
<td>26.93%</td>
<td>$54.87M</td>
<td>-1.16%</td>
</tr>
<tr>
<td>Verizon Communications</td>
<td>Neutral</td>
<td>3.04%</td>
<td>$20.43B</td>
<td>4.91%</td>
</tr>
<tr>
<td>AT&amp;T</td>
<td>Buy</td>
<td>0.72%</td>
<td>$18.59B</td>
<td>4.27%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Telefonica Brasil ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit and Return on Equity.
<h3>Discovering Telefonica Brasil: A Closer Look</h3>
Telefonica Brasil, known as Vivo, is the largest wireless carrier in Brazil with 102 million customers, which is equal to about 39% market share. The firm is strongest in the postpaid business, where it has 67 million customers, or about 41% share of this market. Wireless services and equipment contribute about 70% of total revenue. Vivo is the incumbent fixed-line telephone operator in Sao Paulo state and, following the acquisition of GVT, the owner of an extensive fiber network across the country. The firm provides internet access to 7 million households on this network. The firm also sells pay-TV and phone services to its fixed-line customers. Finally, corporate data and IT services, including cloud computing support, contribute about 9% of total revenue.
<h3>Telefonica Brasil: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Telefonica Brasil showcased positive performance, achieving a revenue growth rate of 6.24% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Telefonica Brasil's net margin is impressive, surpassing industry averages. With a net margin of 7.35%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Telefonica Brasil's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Telefonica Brasil's ROA stands out, surpassing industry averages. With an impressive ROA of 0.84%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Telefonica Brasil's debt-to-equity ratio is below the industry average. With a ratio of 0.3, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/VIV/earnings">To track all earnings releases for Telefonica Brasil visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Telefonica Brasil's Earnings Outlook

Principal Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>) will release its quarterly earnings report on Monday, 2025-07-28. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Principal Finl Gr to report an earnings per share (EPS) of $1.98.
Anticipation surrounds Principal Finl Gr's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 2.05% drop in the share price on the subsequent day.
Here's a look at Principal Finl Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.83</td>
<td>1.93</td>
<td>2.02</td>
<td>1.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.81</td>
<td>1.94</td>
<td>1.76</td>
<td>1.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455717_0.png" alt="eps graph" />
<h3>Tracking Principal Finl Gr's Stock Performance</h3>
Shares of Principal Finl Gr were trading at $80.33 as of July 24. Over the last 52-week period, shares are down 0.92%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PFG/earnings">To track all earnings releases for Principal Finl Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Principal Finl Gr

Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Nucor will report an earnings per share (EPS) of $2.67.
Investors in Nucor are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.13 in the last quarter, leading to a 1.89% increase in the share price on the following day.
Here's a look at Nucor's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.64</td>
<td>0.63</td>
<td>1.47</td>
<td>2.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.77</td>
<td>1.22</td>
<td>1.49</td>
<td>2.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>4.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455707_0.png" alt="eps graph" />
<h3>Nucor Share Price Analysis</h3>
Shares of Nucor were trading at $141.43 as of July 24. Over the last 52-week period, shares are down 10.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/NUE/earnings">To track all earnings releases for Nucor visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Nucor's Earnings Expectations

Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Hartford Finl Servs Gr will report an earnings per share (EPS) of $2.81.
Investors in Hartford Finl Servs Gr are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 0.4% drop in the share price on the subsequent day.
Here's a look at Hartford Finl Servs Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.14</td>
<td>2.64</td>
<td>2.54</td>
<td>2.24</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.20</td>
<td>2.94</td>
<td>2.53</td>
<td>2.50</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-7.000000000000001%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455697_0.png" alt="eps graph" />
<h3>Performance of Hartford Finl Servs Gr Shares</h3>
Shares of Hartford Finl Servs Gr were trading at $123.04 as of July 24. Over the last 52-week period, shares are up 12.29%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HIG/earnings">To track all earnings releases for Hartford Finl Servs Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Hartford Finl Servs Gr's Future Earnings

Barclays analyst Raimo Lenschow maintains SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) with a Overweight and raises the price target from $308 to $322.

Barclays Maintains Overweight on SAP, Raises Price Target to $322

Making a noteworthy insider sell on July 24, Edward H Bastian, Chief Executive Officer at Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), is reported in the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000027904/000168316825005363//Archives/edgar/data/27904/000168316825005363/0001683168-25-005363-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Bastian sold 35,000 shares of Delta Air Lines. The total transaction value is $1,969,974.
At Friday morning, Delta Air Lines shares are up by 0.18%, trading at $54.81.
<h3>All You Need to Know About Delta Air Lines</h3>
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
<h3>Delta Air Lines: Delving into Financials</h3>
Decline in Revenue: Over the 3 months period, Delta Air Lines faced challenges, resulting in a decline of approximately -0.06% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a high gross margin of 30.26%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Delta Air Lines's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 3.28.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.22.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Delta Air Lines's P/E ratio of 7.95 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.57, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Delta Air Lines's EV/EBITDA ratio at 8.44 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000027904">Check Out The Full List Of Delta Air Lines's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Chief Executive Officer At Delta Air Lines Sells $1.97M Of Stock

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-28. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Exelixis will report an earnings per share (EPS) of $0.61.
The market awaits Exelixis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS beat by $0.18 in the last quarter, leading to a 20.84% increase in the share price on the following day.
Here's a look at Exelixis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.49</td>
<td>0.35</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.62</td>
<td>0.55</td>
<td>0.47</td>
<td>0.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>21.0%</td>
<td>-0.0%</td>
<td>13.0%</td>
<td>13.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753455687_0.png" alt="eps graph" />
<h3>Market Performance of Exelixis's Stock</h3>
Shares of Exelixis were trading at $44.79 as of July 24. Over the last 52-week period, shares are up 94.94%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on Exelixis</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis.
The consensus rating for Exelixis is Buy, based on 14 analyst ratings. With an average one-year price target of $48.5, there's a potential 8.28% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Neurocrine Biosciences, Moderna and BioMarin Pharmaceutical, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Neurocrine Biosciences, with an average 1-year price target of $154.0, suggesting a potential 243.83% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Moderna, with an average 1-year price target of $36.83, suggesting a potential 17.77% downside.</li>
<li>Analysts currently favor an Outperform trajectory for BioMarin Pharmaceutical, with an average 1-year price target of $97.75, suggesting a potential 118.24% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Neurocrine Biosciences, Moderna and BioMarin Pharmaceutical, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>30.62%</td>
<td>$536.27M</td>
<td>7.30%</td>
</tr>
<tr>
<td>Neurocrine Biosciences</td>
<td>Buy</td>
<td>11.12%</td>
<td>$563.40M</td>
<td>0.31%</td>
</tr>
<tr>
<td>Moderna</td>
<td>Neutral</td>
<td>-35.93%</td>
<td>$17M</td>
<td>-9.26%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>Outperform</td>
<td>14.84%</td>
<td>$593.59M</td>
<td>3.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Exelixis ranks highest in revenue growth and gross profit among its peers. However, it has the lowest return on equity. Overall, Exelixis is positioned favorably compared to its peers in terms of financial performance.
<h3>Unveiling the Story Behind Exelixis</h3>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Exelixis's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 30.62%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Exelixis's net margin excels beyond industry benchmarks, reaching 28.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Exelixis's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.3% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.52%, the company showcases effective utilization of assets.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/EXEL/earnings">To track all earnings releases for Exelixis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

Uncovering Potential: Exelixis's Earnings Preview

Highlighted on July 24, it was unveiled in an SEC filing that III, Director at Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: Disclosed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001668397/000166839725000091//Archives/edgar/data/1668397/000166839725000091/0001668397-25-000091-index.htm">U.S. Securities and Exchange Commission</a>, III, Director at Medpace Hldgs, executed a strategic derivative sale. This involved exercising stock options for 1,972 shares of MEDP, resulting in a transaction value of $740,111.
As of Friday morning, Medpace Hldgs shares are down by 5.57%, with a current price of $430.3. This implies that III's 1,972 shares have a value of $740,111.
<h3>Delving into Medpace Hldgs's Background</h3>
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
<h3>Unraveling the Financial Story of Medpace Hldgs</h3>
Revenue Growth: Medpace Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 14.24%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 29.84%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Medpace Hldgs's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 3.16.
</li>
</ul>
Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 33.85, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 6.34 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Medpace Hldgs's EV/EBITDA ratio of 25.43 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001668397">Check Out The Full List Of Medpace Hldgs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Ferguson Enterprises

Notizie

Ultime notizie per Ferguson Enterprises (NYSE:FERG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO